CagriSema 2.4/2.4 mg versus CagriSema 1.0/1.0 mg in adults with type 2 diabetes: a dose-comparison systematic review and meta-analysis of randomized controlled trials

In adults with type 2 diabetes, CagriSema 2.4/2.4 mg yields greater weight loss than 1.0/1.0 mg (MD −2.07 pp), with higher GI disorders (64.8% vs 53.2%).

• Why it matters: Direct dose comparisons were missing for once-weekly cagrilintide-semaglutide maintenance doses, leaving uncertainty about balancing additional weight loss against tolerability.
• What they did: A systematic review and meta-analysis of 3 randomized controlled trials (1,506 participants) pooled arm-level contrasts using random-effects models, assessing body weight and HbA1c against prespecified MIDs.
• The result: Weight reduction favored 2.4/2.4 mg (entire CI below the 3 pp MID), while HbA1c differences were not statistically significant (MD −0.16 pp; 95% CI −0.43 to 0.10); GI disorders were more frequent with 2.4/2.4 mg.

AI summary of the abstract · may contain errors · not medical advice · read the paper.